PhilipsPHG
Recorded

Philips 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 7 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the Royal Philips Third Quarter 2026 Results Conference Call on Tuesday, November 3rd, 2026. During the call, hosted by Roy Jakobs, CEO, and Charlotte Hanneman, CFO, all participants will be in a listen-only mode. After the introduction, there will be an opportunity to ask questions. Please note, the results press release and presentation are available on the Investor Relations website. This call will be recorded, and the replay and full transcript of this webcast will be available on the website after this call concludes. We want to draw your attention to the Philips safe harbor statement on the screen and in the presentation. I will now hand the conference over to Charlotte Hanneman.

Charlotte HannemanCFO

Please go ahead, ma'am. Good morning, everyone, and thank you for joining us.

Charlotte HannemanCFO

Before we start, a quick update on our Investor Relations team. As you may have seen in our announcement earlier today, Dorin Danu is taking over as our Head of Investor Relations. Many of you will already know Dorin well, and his experience and strong relationships across our investor community will ensure continuity and an open, constructive dialogue. Durga Doraisamy is leaving Philips, and we thank her for her contribution and wish her all the best for the future. With that, Roy, over to you.

Roy JakobsCEO

Good morning, everyone. Let me start with an overview of our Q3 performance. We delivered an excellent order intake growth of 8%, driven by sustained customer demand and further traction from our recently launched innovations, supporting near and mid-term sales delivery. Comparable sales grew approximately 3%, driven by strength in Personal Health and Connected Care. Diagnosis & Treatment was broadly flat, reflecting the phasing of certain ultrasound shipments and lower sales in China, as communicated in our Q2 release. Our innovations and productivity measures drove significant margin expansion across all business segments. Adjusted EBITA margin increased by 70 basis points to 13%, ahead of our expectations. Free cash flow was a strong inflow of EUR 384 million. We continue to make progress on Respironics-related legal proceedings.

Roy JakobsCEO

The Respironics agreement in principle with the U.S. Department of Justice marks an important step in resolving the consequences of the sleep and respiratory care recall. As a result, Philips recorded a provision of EUR 288 million. Our year-to-date performance keeps us well on track for the full year. Order intake is up 4%. Comparable sales growth is within our full-year range at 3.5%, and underlying margins have expanded by 30 basis points despite inflation and tariffs. This reinforces our confidence in delivering the first year of our plan and in the medium-term trajectory we outlined at Capital Markets Day. We reiterate our full-year outlook for comparable sales growth, Adjusted EBITA margin, and free cash flow. Let me expand on our orders. Equipment order intake grew 8%, building on an 8% increase in the prior year quarter, driven by very strong performance in Diagnosis & Treatment and growth across all regions.

Roy JakobsCEO

Our equipment order book has increased both sequentially and year-on-year, providing good visibility in future sales, including the near term. Turning first to Diagnosis & Treatment. Order intake growth approached 20%, with both Image Guided Therapy and Precision Diagnosis delivering double-digit order growth, supported by broad-based growth across modalities and regions. In Image Guided Therapy, this double-digit growth came on top of an already solid comparable. North America was particularly strong. As health systems consolidate, purchasing decisions remain primarily driven by clinical differentiation, productivity gains, and long-term strategic value rather than price alone. This is where our open, integrated interventional platform, combining systems, devices, software, and AI across the clinical workflow, gives us a distinct competitive advantage and sets the industry standard, while helping customers to drive productivity and generate revenue reliably over the long term.

Roy JakobsCEO

We secured vendor-of-choice positions at major U.S. health systems where competitors have established relationships for more than a decade, breaking through long-standing barriers to entry. This opens up significant new opportunities to capture market share by dislodging incumbents and expanding our install base. Within Precision Diagnosis, the innovation pipeline we presented at Capital Markets Day continues to gain commercial traction, contributing to a very strong double-digit order intake growth in the quarter. Importantly, we have reached a turning point in rebuilding the Precision Diagnosis order book, which has now expanded for 3 consecutive quarters. Strong customer wins and sustained order momentum as we exit in Q3 reinforce our confidence in the growth trajectory of this business. Looking at some of the key highlights from the quarter, we are particularly pleased with the strongly increasing customer demand for our CT portfolio.

Roy JakobsCEO

In the premium segment, we continue to scale our industry-leading spectral CT portfolio, including CT 7500 and AI-enabled Verida, building on a foundation of over 1,250 clinical publications, providing strong clinical evidence for use of spectral technology. The order book for these spectral CT platforms grew double digits year on year, with Verida becoming an increasingly meaningful contributor. In the performance segment, our AI-enabled productivity workhorse CT 5300 is also gaining traction, with its order book nearly doubling year on year. We see opportunities to build on this momentum with existing customers, but also to reach new segments, including private and outpatient imaging centers. In MR, our helium-free BlueSeal systems delivered strong order growth in the quarter. Philips continues to lead the industry in its transition to helium-free MR. Around 70% of our MR systems shipped year to date were helium-free.

Roy JakobsCEO

Subject to regulatory approvals, we expect BlueSeal Horizon, the industry's first 3T helium-free MR platform, to begin contributing to taking order intake from 2027 onwards. In ultrasound, demand for EPIQ CVx remains strong in cardiovascular imaging, and we are extending our cardiovascular excellence into other clinical settings. Flash is gaining traction in point-of-care ultrasound. In general imaging, Alturion recently received FDA clearance and began securing its first orders in Q3. In Connected Care, order intake declined mid-single digit in Q3, against a particularly high prior year comparison of more than 20% last year. Customer engagement remained very strong, as we continue to win major competitive deals by dislodging incumbents, reflected in our strong monitoring order book. In monitoring, the larger agreements that shifted from Q2 were booked as expected.

Roy JakobsCEO

Longer negotiation and contracting cycles for some major enterprise-wide standardization agreements resulted in several orders shifting into Q4 as well. In the quarter, we signed several long-term Monitoring as a Service agreements, including one with Avera Health in the U.S., supporting standardized patient monitoring across 24 hospitals. In enterprise informatics, Ontario Health selected the Philips Enterprise Imaging Vendor Neutral Archive to modernize province-wide imaging infrastructure, supporting the sharing of more than 20 million imaging studies annually across more than 150 hospitals and 50 imaging clinics. Turning to Personal Health, we delivered another quarter of broad-based growth across businesses and regions, resulting in a strong 8% comparable sales growth. We continue to scale our proven growth model across core platforms such as Sonicare, high-end shaving, OneBlade, Lumea IPL, and Avent.

Roy JakobsCEO

Our category leadership, combined with innovation, premiumization, and strong commercial execution, is driving consumer demand, helping us to secure more shelf space with key retail partners and expanding distribution. This momentum is reflected in sustained market share gains and strong sell-out trends across all businesses, alongside category growth that we are driving for key retail partners. As we continue to innovate, we support our launches with investment in customer activation and consumer awareness to sustain this momentum and build long-term demand. Innovation continues to strengthen our differentiation across the portfolio. In Image Guided Therapy, we are investing EUR 50 million in AI, robotics, and advanced imaging in the Netherlands, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing. In the U.S., an ARPA-H award up to $34 million will support AI-enabled robotic stroke care on the Azurion platform.

Roy JakobsCEO

In MR, together with Imricor, we introduced the first commercially available cardiac interventional MR lab solution, enabling radiation-free, MR-guided cardiac interventions. In Personal Health, we launched the Lumea 9900 Pro, the first at-home IPL device with real-time audio feedback and motion guidance, which received a special mention on TIME's 2026 Best Inventions list. These examples demonstrate how we are combining AI, clinical leadership, and differentiated technologies to extend our leadership positions and create new growth opportunities across the portfolio. Our disciplined execution starts with patient safety and quality, our highest priority. Strengthening our quality systems and embedding a patient safety-first culture is a multi-year journey, and we continue to make progress. We continue to improve the timelines in corrective and preventive actions and on-time medical device reporting. Our focus remains on taking appropriate actions to further strengthen end-to-end quality and regulatory discipline.

Roy JakobsCEO

On supply chain, we continue to strengthen the reliability, resilience, and efficiency of our end-to-end supply chain. Despite continued geopolitical uncertainty and increasing demand for electronic components, including from AI infrastructure, service levels improved further year-on-year, helping us to deliver more reliably for our customers. We continue to strengthen supply chain resilience through dual sourcing and by expanding our supplier network. We are also advancing our service excellence agenda while continuing to regionalize and selectively localize our supply chain and service footprint, bringing parts and capabilities closer to our customers. In Indonesia, for example, we opened a new parts distribution center in Jakarta, strengthening local service capability while leveraging our global network. Looking at our regions, consumer sentiment remained resilient in North America, was positive in Europe, and also positive in selected international regions. In China, it was subdued and broadly unchanged.

Roy JakobsCEO

Hospital demand in Q3 was strong across North America and international regions. Let me share more color on the regional dynamics. In North America, we delivered order growth, following strong double-digit growth in the prior year quarter. We expect this growth to continue. Healthy patient volumes, procedural growth, and sustained capital investment by large health systems continue to support demand. Customers increasingly want to standardize care through fewer, deeper strategic partnerships. As market leaders in patient monitoring and Image Guided Therapy in North America, our platform-based portfolio, differentiated innovation, and deep long-standing customer relationships position us well to capture this demand. Our sustained order momentum and healthy pipeline reinforce our confidence in North America's role as core growth engine for Philips in 2026 and over the midterm. Turning to Europe. Order intake was robust for another quarter. European health systems are investing in productivity, digitization, and modernizing care delivery.

Roy JakobsCEO

Our differentiated portfolio and commercial execution continue to resonate well with customers. This gives us the confidence that Europe will remain an increasingly important contributor to our growth. In China, order intake grew, supported by the timing of the renewal program and a weaker prior year comparison. We remain prudent in assessing the sustainability of this momentum, as centralized procurement continues to expand. Our cautious view on the market in the near term therefore remains unchanged. For the full year, we continue to expect China sales to be broadly stable, with growth in Personal Health offsetting a decline in health system businesses. In remaining growth regions, we continue to see healthy demand, supported by investments in healthcare infrastructure and digitization. In Q3, demand was particularly strong across Latin America, India, and Asia Pacific. I will now hand over back to Charlotte.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day